{ "A Study of SNP-ACTH (1-39) Gel for Primary Membranous Nephropathy", "This study is testing SNP-ACTH (1-39) Gel against Rituximab for people with primary membranous nephropathy (PMN), a kidney disease. The study aims to find the best dose of SNP-ACTH (1-39) Gel and then compare its effectiveness to Rituximab over 24 months. You may be able to join if you are 18 or older, have PMN confirmed by a biopsy or a positive anti-PLA2R antibody test, and are at high risk for kidney function loss. Success will be measured by changes in protein in your urine, levels of certain antibodies, and whether your PMN completely responds to treatment. The current recruitment status is unclear.", "design": "This study is an open-label, two-phase trial comparing SNP-ACTH (1-39) Gel to Rituximab. It will involve up to 148 participants who will be randomly assigned to different treatments.", "commitments": "In Phase 3a, you would receive SNP-ACTH (1-39) Gel injections three times per week for 12 months. In Phase 3b, you would receive either SNP-ACTH (1-39) Gel at the chosen dose for 12 months or Rituximab over two treatment cycles at month 1 and month 6.", "compensation": "Not stated in the trial record.", "follow_up": "Your progress will be measured at various times up to 12 months for changes in urine protein and antibody levels, and up to 24 months for complete response of PMN.", }

Study design

Not specified.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.